{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-026965","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2026-06-03T11:00:17+00:00","discovered_at":"2026-06-03T11:05:00.318854+00:00","generated_at":"2026-06-03T11:05:43.135403+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Sam Lee and Jim Martin","bullets":["James Sapirstein appointed CEO effective June 3, 2026, replacing Sam Lee and Jim Martin as co-CEOs.","Sam Lee becomes President and Chief Scientific Officer; Jim Martin remains CFO.","Sapirstein has led 23 product launches and served as CEO of Contravir and Tobira Therapeutics.","Company plans to appoint Sapirstein to the Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026965","json":"https://secwatch.observer/filing/0001493152-26-026965.json","markdown":"https://secwatch.observer/filing/0001493152-26-026965.md","text":"https://secwatch.observer/filing/0001493152-26-026965.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226026965/0001493152-26-026965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226026965/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T11:05:43.135403+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}